Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.36 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL5874760 | 1.00 | TSHR (0.56) | TSHRTP53CYP2C9PDE4ATDP1 | |
| Lactic Acid SCHEMBL971160 | 0.83 | TP53 (0.61) | TP53TDP1CHRM1AKR1A1CHRM3 | |
| Cadaverine Tartrate SCHEMBL18987140 | 0.82 | TSHR (0.71) | TSHRTP53CYP2C9PDE4ATDP1 | |
| Cadaverine Tartrate SCHEMBL6306249 | 0.81 | TSHR (0.53) | TSHRTP53CYP2C9PDE4ATDP1 | |
| Cadaverine Tartrate SCHEMBL27469398 | 0.81 | TSHR (0.53) | TSHRTP53CYP2C9PDE4ATDP1 | |
| SCHEMBL1828280 | 0.80 | TP53 (0.40) | TSHRTP53TDP1CHRM1AKR1A1 | |
| Cadaverine Tartrate SCHEMBL282045 | 0.79 | TSHR (0.67) | TSHRTP53CYP2C9PDE4ATDP1 | |
| Cadaverine Tartrate SCHEMBL2158124 | 0.79 | TSHR (0.67) | TSHRTP53CYP2C9PDE4ATDP1 | |
| Tartaric Acid SCHEMBL30771976 | 0.79 | TSHR (0.67) | TSHRTP53CYP2C9PDE4ATDP1 | |
| Cadaverine Tartrate SCHEMBL5874575 | 0.79 | TSHR (0.50) | TSHRTP53CYP2C9PDE4ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114369129-A | Synthetic method of chlorinated nicotinamide ribose | 宁波新凯生物科技有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-119684381-A | Crystalline forms of nicotinamide riboside furanoside salts and nutritional supplements and pharmaceutical compositions containing same | 生物合成股份公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119462782-A | Method for producing nicotinamide riboside salts, nicotinamide riboside salts per se and use thereof | 生物合成股份公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-114423771-A | Method for producing nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts themselves and use thereof | 生物合成股份公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114369129-A | Synthetic method of chlorinated nicotinamide ribose | 宁波新凯生物科技有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114369129-A | Synthetic method of chlorinated nicotinamide ribose | 宁波新凯生物科技有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-106459147-B | Serine derivatives as ghrelin receptor agonists | 拉夸里亚创药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2020-06-11 | — | — | US | disclosed |
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3518878-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | Henkel AG & Co. KGaA (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3131916-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-9259402-B2 | Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyI)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-02-16 | — | — | US | disclosed |
| WO-2016021191-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-02-11 | — | — | WO | disclosed |
| US-20150190351-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2015-07-09 | — | — | US | disclosed |
| US-7128976-B2 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| CN-1837205-A | Process for the preparation of pyrazolopyridine tartrates | PFIZER PROD INC (US) | 2006-09-27 | — | — | CN | disclosed |
| CN-1515570-A | Preparation method of pyrazolo [4, 3-c ] pyridine-3-ketone L-tartrate | �Ʒ� | 2004-07-28 | — | — | CN | disclosed |
| CN-1137891-C | Process for preparing growth hormone secretagogue | �Ʒ� | 2004-02-11 | — | — | CN | disclosed |
| US-20030091838-A1 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2003-05-15 | — | — | US | disclosed |
| CN-1270960-A | Process for preparing growth hormone secretagogue | PFIZER PROD INC (US) | 2000-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, S100A10 | CHRM1 2176/4885CHRM3 2150/4885HTR2A 267/4885 |
| US-20150190351-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | AR, BRCA1, CYP17A1 | CHRM1 2544/4885CHRM3 3331/4885HTR2A 1516/4885 |
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, DSG1 | CHRM1 1565/4885CHRM3 1661/4885HTR2A 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.